Second/third/fourth line therapy with tyrosine kinase inhibitors in NSCLC

被引：0
作者：
Van Zandwijk, N [1 ]
Baas, P [1 ]
机构：
[1] Antoni Van Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Thorac Oncol, Amsterdam, Netherlands
来源：
TUMORI | 2002年
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S37 / S38
页数：2
相关论文
共 50 条
  • [41] Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of NSCLC
    Pallis, A. G.
    Syrigos, K. N.
    LUNG CANCER, 2013, 80 (02) : 120 - 130
  • [42] Activity of EGFR Tyrosine Kinase Inhibitors in NSCLC With Refractory Leptomeningeal Metastases
    Flippot, Ronan
    Biondani, Pamela
    Auclin, Edouard
    Xiao, Dingyu
    Hendriks, Lizza
    Le Rhun, Emilie
    Leduc, Charlotte
    Beau-Faller, Michele
    Gervais, Radj
    Remon, Jordi
    Adam, Julien
    Planchard, David
    Lavaud, Pernelle
    Naltet, Charles
    Caramella, Caroline
    Le Pechoux, Cecile
    Lacroix, Ludovic
    Gazzah, Anas
    Mezquita, Laura
    Besse, Benjamin
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (08) : 1400 - 1407
  • [43] Outcome After Failure of Second Generation Tyrosine Kinase Inhibitors Treatment As First-line Therapy for Patients With Chronic Myeloid Leukemia
    Eghtedar, Alireza
    Kantarjian, Hagop
    Jabbour, Elias
    O'Brien, Susan
    Burton, Elizabeth
    Garcia-Manero, Guillermo
    Verstovsek, Srdan
    Ravandi, Farhad
    Borthakur, Gautam
    Konopleva, Marina
    Quintas-Cardama, Alfonso
    Cortes, Jorge
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2013, 13 (04) : 477 - 484
  • [44] Janus Kinase Inhibitors as a Third-Line Therapy for Refractory Endogenous Noninfectious Uveitis
    Garweg, Justus G.
    Straessle, Kim A.
    OCULAR IMMUNOLOGY AND INFLAMMATION, 2024,
  • [45] Advanced ALK plus NSCLC Third-generation Tyrosine Kinase Inhibitor available for First-line Use
    Freye, Reimund
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (05)
  • [46] Second- or third-generation tyrosine kinase inhibitors in first-line treatment of chronic myeloid leukemia in general population: Is there a real benefit?
    Canet, Jim
    Cony-Makhoul, Pascale
    Orazio, Sebastien
    Cornet, Edouard
    Troussard, Xavier
    Maynadie, Marc
    Etienne, Gabriel
    Monnereau, Alain
    CANCER MEDICINE, 2021, 10 (20): : 6959 - 6970
  • [47] Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations
    Arrieta, Oscar
    Catalan, Rodrigo
    Guzman-Vazquez, Silvia
    Barron, Feliciano
    Lara-Mejia, Luis
    Soto-Molina, Herman
    Ramos-Ramirez, Maritza
    Flores-Estrada, Diana
    de la Garza, Jaime
    BMC CANCER, 2020, 20 (01)
  • [48] Immune checkpoint inhibitors plus VEGF tyrosine kinase inhibitors as second-line or later therapy for patients with extensive stage small cell lung cancer
    Yan, N.
    Guo, S. X.
    Li, M. J.
    Huang, S. Y.
    Guo, Q. Q.
    Geng, D.
    Zhang, H. X.
    Li, X.
    ANNALS OF ONCOLOGY, 2021, 32 : S1168 - S1168
  • [49] Unique Cutaneous Reaction to Second-and Third-Generation Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia
    Patel, Anisha B.
    Solomon, Alvin R.
    Mauro, Michael J.
    Ehst, Benjamin D.
    DERMATOLOGY, 2016, 232 (01) : 122 - 125
  • [50] Unique cutaneous reaction to second- and third-generation tyrosine kinase inhibitors for chronic myeloid leukemia
    Patel, A.
    Solomon, A.
    Mauro, M.
    Ehst, B. D.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S44 - S44
12345